Latest Peplin news

news

09-Jan-09

Positive results for Peplin's Phase IIb AK Trial read more

16-Dec-08

Peplin completes enrolment for its first phase III AK clinical trial read more

02-Dec-08

Form 10-Q - Quarterly Report read more

Registration statement including financial report read more

Privacy policy

Peplin Limited (“Peplin”) is committed to protecting the personal information it collects and is bound by the National Privacy Principles.

The information that Peplin collects about you depends on your interaction with us. If you are a shareholder or supporter of Peplin for example, we may collect details such as name, address, phone/fax numbers and email address, primarily for the purpose of providing you with relevant information about Peplin and its activities.

Generally, we will only collect personal information directly from you, and use this information only for the purpose of providing you with information and advice relating to matters of relevance to you.

We do not sell, rent or disclose your personal information to any third parties without your consent.

Peplin takes all reasonable measures to ensure that your personal information is stored or secured safely.

If you wish to know the personal information we hold about you, please submit a request for access in writing to the contact details below. If complying with your request requires considerable time and expense on our part, we may charge you a reasonable fee for providing you with copies of the information.

If you require access, or have any other concerns about the way Peplin handles your personal information, please contact us at the address set out below:

The Privacy Officer

Peplin Limited
Level 2
Brisbane Portal
1 Breakfast Creek Road
NEWSTEAD QLD 4006

Email: privacy@peplin.com
Tel: +61 7 3250 1200